Cargando…

Harnessing Oncolytic Virus-Mediated Anti-Tumor Immunity

Detalles Bibliográficos
Autores principales:	Schirrmacher, Volker, Fournier, Philippe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2014
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4241813/ https://www.ncbi.nlm.nih.gov/pubmed/25505735 http://dx.doi.org/10.3389/fonc.2014.00337

Ejemplares similares

Multimodal Cancer Therapy Involving Oncolytic Newcastle Disease Virus, Autologous Immune Cells, and Bi-Specific Antibodies
por: Schirrmacher, Volker, et al.
Publicado: (2014)

Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host
por: Fournier, Philippe, et al.
Publicado: (2013)

Molecular Mechanisms of Anti-Neoplastic and Immune Stimulatory Properties of Oncolytic Newcastle Disease Virus
por: Schirrmacher, Volker
Publicado: (2022)

Pharmacological Modulation of Anti-Tumor Immunity Induced by Oncolytic Viruses
por: Forbes, Nicole E., et al.
Publicado: (2014)

Remodeling of Tumor Immune Microenvironment by Oncolytic Viruses
por: Zhang, Bin, et al.
Publicado: (2021)

Oncolytic Virus-Mediated Reversal of Impaired Tumor Antigen Presentation
por: Gujar, Shashi A., et al.
Publicado: (2014)

Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy
por: Schirrmacher, Volker, et al.
Publicado: (2022)

Hacking the Immune Response to Solid Tumors: Harnessing the Anti-Cancer Capacities of Oncolytic Bacteria
por: Roe, Jason M., et al.
Publicado: (2023)

Newcastle Disease Virus: A Promising Vector for Viral Therapy, Immune Therapy, and Gene Therapy of Cancer
por: Schirrmacher, Volker, et al.
Publicado: (2008)

Oncolytic Viruses—Interaction of Virus and Tumor Cells in the Battle to Eliminate Cancer
por: Howells, Anwen, et al.
Publicado: (2017)

Harnessing the Anti-Tumor Mediators in Mast Cells as a New Strategy for Adoptive Cell Transfer for Cancer
por: Fereydouni, Mohammad, et al.
Publicado: (2022)

New Insights into Mechanisms of Long-term Protective Anti-tumor Immunity Induced by Cancer Vaccines Modified by Virus Infection
por: Schirrmacher, Volker
Publicado: (2020)

Tumor Antigen-Dependent and Tumor Antigen-Independent Activation of Antitumor Activity in T Cells by a Bispecific Antibody-Modified Tumor Vaccine
por: Fournier, Philippe, et al.
Publicado: (2010)

Oncolytic Viruses as Anticancer Vaccines
por: Woller, Norman, et al.
Publicado: (2014)

Modulation of the Intratumoral Immune Landscape by Oncolytic Herpes Simplex Virus Virotherapy
por: Yin, Jie, et al.
Publicado: (2017)

Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy
por: Schirrmacher, Volker, et al.
Publicado: (2019)

Cancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis
por: Schirrmacher, Volker
Publicado: (2020)

Immunotherapeutic Potential of Oncolytic Vaccinia Virus
por: Thorne, Steve H.
Publicado: (2014)

The Oncolytic Virus in Cancer Diagnosis and Treatment
por: Cao, Guo-dong, et al.
Publicado: (2020)

Canine Parvovirus and Its Non-Structural Gene 1 as Oncolytic Agents: Mechanism of Action and Induction of Anti-Tumor Immune Response
por: Arora, Richa, et al.
Publicado: (2021)

Oncolytic Adenoviral Vector-Mediated Expression of an Anti-PD-L1-scFv Improves Anti-Tumoral Efficacy in a Melanoma Mouse Model
por: Vitale, Maria, et al.
Publicado: (2022)

Immune System, Friend or Foe of Oncolytic Virotherapy?
por: Filley, Anna C., et al.
Publicado: (2017)

Clinical Trials of Oncolytic Viruses in Breast Cancer
por: Carter, Mary E., et al.
Publicado: (2021)

Retraction: The oncolytic virus in cancer diagnosis and treatment
Publicado: (2023)

Armed oncolytic viruses: A kick-start for anti-tumor immunity
por: de Graaf, J.F., et al.
Publicado: (2018)

Harnessing the immune system in the treatment of cutaneous T cell lymphomas
por: Fay, Christopher J., et al.
Publicado: (2023)

Monitoring the Efficacy of Oncolytic Viruses via Gene Expression
por: Ansel, Ashley, et al.
Publicado: (2017)

Oncolytic Viruses—Natural and Genetically Engineered Cancer Immunotherapies
por: Jhawar, Sachin R., et al.
Publicado: (2017)

Oncolytic virus: A catalyst for the treatment of gastric cancer
por: Wang, Junqing, et al.
Publicado: (2022)

Recent advances in oncolytic virus therapy for hepatocellular carcinoma
por: Zhu, Licheng, et al.
Publicado: (2023)

Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities
por: Yamamoto, Leona, et al.
Publicado: (2021)

Editorial: Oncolytic Viruses—Genetically Engineering the Future of Cancer Therapy
por: Gesundheit, Benjamin, et al.
Publicado: (2017)

Oncolytic Viruses and Cancer, Do You Know the Main Mechanism?
por: Kooti, Wesam, et al.
Publicado: (2021)

Senecavirus A as an Oncolytic Virus: Prospects, Challenges and Development Directions
por: Luo, Dankun, et al.
Publicado: (2022)

Harnessing Pandemonium: The Clinical Implications of Tumor Heterogeneity in Ovarian Cancer
por: Blagden, Sarah P.
Publicado: (2015)

Attacking Postoperative Metastases using Perioperative Oncolytic Viruses and Viral Vaccines
por: Tai, Lee-Hwa, et al.
Publicado: (2014)

Herpes simplex virus 1 as an oncolytic viral therapy for refractory cancers
por: Scanlan, Hayle, et al.
Publicado: (2022)

Oncolytic Adenovirus—A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC
por: Abudoureyimu, Mubalake, et al.
Publicado: (2019)

Prospect of Plasmacytoid Dendritic Cells in Enhancing Anti-Tumor Immunity of Oncolytic Herpes Viruses
por: Schuster, Philipp, et al.
Publicado: (2019)

Editorial: Exploring oncolytic virus-mediated changes in immune microenvironment and immune cells in solid tumors
por: Zhang, Hongwei
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1loo0h2vtqokp47vm7udm9tmtk